← Back to Clinical Trials
Recruiting NCT03981497

NCT03981497 Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03981497
Status Recruiting
Phase
Sponsor Francesco De Cobelli
Condition Liver Cancer
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2018-02-28
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Microwave ablation (MWA)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2018-02-28 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA. Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path

Eligibility Criteria

Inclusion Criteria: * \> 18 years with primary or secondary liver tumors or small kidney tumors that are not candidates for surgery or cannot be radically resected by surgery alone * Primary liver cancer: up to three liver nodules ≤ 3 cm * Secondary hepatic tumours: up to nodules ≤ 3 cm provided that the objective is complete hepatic clearance Renal tumours: single or multiple (von Hippel Lindau syndrome), \< 4 cm Exclusion Criteria: * pregnant women * non-manageable coagulopathies * Extended extrahepatic or extrarenal disease * for liver ablation: presence of bilio-digestive anastomosis

Contact & Investigator

Central Contact

Francesco De Cobelli, MD

✉ decobelli.francesco@hsr.it

📞 +390226432529

Frequently Asked Questions

Who can join the NCT03981497 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03981497 currently recruiting?

Yes, NCT03981497 is actively recruiting participants. Contact the research team at decobelli.francesco@hsr.it for enrollment information.

Where is the NCT03981497 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT03981497 clinical trial?

NCT03981497 is sponsored by Francesco De Cobelli. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology